Publication: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
No Thumbnail Available
Identifiers
Date
2022-06-01
Authors
Capra, Marcelo
Martin, Thomas
Moreau, Philippe
Baker, Ross
Pour, Ludek
Min, Chang-Ki
Leleu, Xavier
Mohty, Mohamad
Reinoso Segura, Marta
Turgut, Mehmet
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Ferrata storti foundation
Metrics
Export
Abstract
Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) versus Kd in relapsed MM. This subgroup analysis examined results from patients with RI, defined as estimated glomerular filtration rate = 3 treatment-emergent adverse events was similar between the two arms (79.1% in Isa-Kd vs. 77.8% in Kd). In summary, the addition of Isa to Kd improved clinical outcomes with a manageable safety profile in patients with RI, consistent with the benefit observed in the overall IKEMA study population.
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
Low-dose dexamethasone, Pooled analysis, Open-label, Phase-iii, Lenalidomide, Bortezomib, Dialysis, Failure, Complications, Reversibility